Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats
- PMID: 18634811
- DOI: 10.1016/j.neuropharm.2008.06.034
Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats
Abstract
Fentanyl is a potent mu-opioid receptor agonist that is widely used for the treatment of chronic pain. The aim of the present study was to investigate the effect of the dose of fentanyl and the exposure duration on the affective and somatic signs of fentanyl withdrawal in rats. Fentanyl and saline were chronically administered via osmotic minipumps. A discrete-trial intracranial self-stimulation procedure was used to provide a measure of brain reward function and somatic signs were recorded from a checklist of opioid abstinence signs. The opioid receptor antagonist naloxone elevated the brain reward thresholds of the rats chronically treated with high doses of fentanyl (0.3 and 0.6mg/kg/day), but not those of rats treated with low doses of fentanyl (0.006 and 0.06mg/kg/day). Fentanyl had a dose-dependent effect on the naloxone-induced elevations in brain reward thresholds. On a similar note, the discontinuation of the administration of high doses of fentanyl was associated with elevations in brain reward thresholds and the discontinuation of the administration of low doses of fentanyl did not lead to an elevation in brain reward thresholds. The results also demonstrated that the duration of fentanyl administration does not affect naloxone-induced elevation in brain reward thresholds. In contrast, the somatic withdrawal syndrome gradually developed over time; maximum somatic signs were observed 120h after pump implantation. These studies suggest that the magnitude and duration of the negative affective signs of fentanyl withdrawal depend on the dose of fentanyl administered and not on the duration of fentanyl administration.
Similar articles
-
Severe deficit in brain reward function associated with fentanyl withdrawal in rats.Biol Psychiatry. 2006 Mar 1;59(5):477-80. doi: 10.1016/j.biopsych.2005.07.020. Epub 2005 Sep 19. Biol Psychiatry. 2006. PMID: 16169528
-
The effects of buprenorphine on fentanyl withdrawal in rats.Psychopharmacology (Berl). 2007 May;191(4):931-41. doi: 10.1007/s00213-006-0670-2. Epub 2007 Jan 9. Psychopharmacology (Berl). 2007. PMID: 17211652
-
Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects.J Pharmacol Exp Ther. 2000 Mar;292(3):1053-64. J Pharmacol Exp Ther. 2000. PMID: 10688623
-
Antagonist treatment of opioid withdrawal translational low dose approach.J Addict Dis. 2006;25(2):1-8. doi: 10.1300/J069v25n02_01. J Addict Dis. 2006. PMID: 16785213 Review.
-
Myoclonus secondary to withdrawal from transdermal fentanyl: case report and literature review.J Pain Symptom Manage. 2002 Jan;23(1):66-72. doi: 10.1016/s0885-3924(01)00370-0. J Pain Symptom Manage. 2002. PMID: 11779671 Review.
Cited by
-
Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.Clin Pharmacokinet. 2018 Mar;57(3):393-417. doi: 10.1007/s40262-017-0609-2. Clin Pharmacokinet. 2018. PMID: 29178007
-
Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).Postgrad Med. 2009 Nov;121(6):176-96. doi: 10.3810/pgm.2009.11.2087. Postgrad Med. 2009. PMID: 19940429 Free PMC article. Review.
-
Lipophilic analogues of D-cysteine prevent and reverse physical dependence to fentanyl in male rats.Front Pharmacol. 2024 Apr 5;14:1336440. doi: 10.3389/fphar.2023.1336440. eCollection 2023. Front Pharmacol. 2024. PMID: 38645835 Free PMC article.
-
Impairments in expression of devaluation in a Pavlovian goal-tracking task, but not a free operant devaluation task, after fentanyl exposure in female rats.Behav Brain Res. 2024 Feb 26;458:114761. doi: 10.1016/j.bbr.2023.114761. Epub 2023 Nov 17. Behav Brain Res. 2024. PMID: 37977341 Free PMC article.
-
Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.Behav Pharmacol. 2013 Sep;24(5-6):459-70. doi: 10.1097/FBP.0b013e328364c0bd. Behav Pharmacol. 2013. PMID: 23881045 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials